Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RIFAMPIN Cause C-reactive protein increased? 123 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 123 reports of C-reactive protein increased have been filed in association with RIFAMPIN (Rifampin). This represents 0.9% of all adverse event reports for RIFAMPIN.

123
Reports of C-reactive protein increased with RIFAMPIN
0.9%
of all RIFAMPIN reports
1
Deaths
81
Hospitalizations

How Dangerous Is C-reactive protein increased From RIFAMPIN?

Of the 123 reports, 1 (0.8%) resulted in death, 81 (65.9%) required hospitalization, and 5 (4.1%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RIFAMPIN. However, 123 reports have been filed with the FAERS database.

What Other Side Effects Does RIFAMPIN Cause?

Drug ineffective (1,238) Drug reaction with eosinophilia and systemic symptoms (1,049) Drug interaction (735) Pyrexia (735) Acute kidney injury (684) Drug-induced liver injury (684) Off label use (640) Condition aggravated (597) Nausea (572) Paradoxical drug reaction (570)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which RIFAMPIN Alternatives Have Lower C-reactive protein increased Risk?

RIFAMPIN vs RIFAMYCIN RIFAMPIN vs RIFAPENTINE RIFAMPIN vs RIFAXIMIN RIFAMPIN vs RILMENIDINE RIFAMPIN vs RILONACEPT

Related Pages

RIFAMPIN Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased RIFAMPIN Demographics